Gilead Sciences (NASDAQ:GILD) Receives New Coverage from Analysts at Sanford C. Bernstein

Sanford C. Bernstein began coverage on shares of Gilead Sciences (NASDAQ:GILD) in a research note released on Thursday morning, MarketBeat Ratings reports. The firm issued an outperform rating and a $105.00 price objective on the biopharmaceutical company’s stock.

A number of other brokerages have also issued reports on GILD. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Robert W. Baird reiterated a “neutral” rating and set a $80.00 target price on shares of Gilead Sciences in a report on Thursday, June 20th. BMO Capital Markets lifted their price objective on Gilead Sciences from $80.00 to $85.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Barclays lifted their target price on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a research report on Monday, October 7th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $95.00 target price on shares of Gilead Sciences in a research report on Wednesday, September 11th. Ten equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $86.37.

Gilead Sciences Trading Down 0.7 %

NASDAQ:GILD opened at $86.72 on Thursday. The stock has a fifty day moving average price of $81.06 and a two-hundred day moving average price of $72.82. The stock has a market capitalization of $108.04 billion, a price-to-earnings ratio of 240.89, a PEG ratio of 2.98 and a beta of 0.18. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $87.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The business had revenue of $6.95 billion during the quarter, compared to analysts’ expectations of $6.64 billion. As a group, sell-side analysts anticipate that Gilead Sciences will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, September 27th. Investors of record on Friday, September 13th were paid a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 3.55%. The ex-dividend date was Friday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is currently 855.56%.

Insiders Place Their Bets

In other news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the transaction, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the completion of the sale, the insider now directly owns 100,189 shares in the company, valued at approximately $8,398,843.87. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Johanna Mercier sold 29,357 shares of the stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,033,340 over the last three months. Insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Large investors have recently added to or reduced their stakes in the business. RFG Advisory LLC grew its position in shares of Gilead Sciences by 16.9% during the 1st quarter. RFG Advisory LLC now owns 22,514 shares of the biopharmaceutical company’s stock valued at $1,649,000 after purchasing an additional 3,249 shares in the last quarter. First Affirmative Financial Network increased its position in shares of Gilead Sciences by 3.5% in the first quarter. First Affirmative Financial Network now owns 4,342 shares of the biopharmaceutical company’s stock valued at $318,000 after acquiring an additional 147 shares during the period. Gulf International Bank UK Ltd raised its stake in Gilead Sciences by 0.7% in the first quarter. Gulf International Bank UK Ltd now owns 103,231 shares of the biopharmaceutical company’s stock worth $7,561,000 after buying an additional 712 shares in the last quarter. Foundation Resource Management Inc. raised its stake in Gilead Sciences by 2.6% in the first quarter. Foundation Resource Management Inc. now owns 205,686 shares of the biopharmaceutical company’s stock worth $15,067,000 after buying an additional 5,261 shares in the last quarter. Finally, &PARTNERS bought a new position in shares of Gilead Sciences during the first quarter valued at approximately $309,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.